IJCRR

IJCRR - 11(24), December, 2019

Pages: 11-17

Comparative Efficacy of 3Dimensional (3D) Cell Culture Organoids Vs 2Dimensional (2D) Cell Cultures Vs Experimental Animal Models In Disease modeling, Drug development, And Drug Toxicity Testing

Author: Santenna Chenchula, Sunil Kumar, Shoban Babu V

Category: Healthcare

[Download PDF]

Abstract:

Historically animal studies and 2D cell culture models have been strengthening biomedical and pharmaceutical research, with many limitations. Currently, new drug development for many diseases like cancer is an important necessity. An organoid is a miniaturized version of an organ produced in vitro that shows realistic micro-anatomy, is capable of self-renewal and self-organization and exhibits similar functionality as the tissue of origin. While their size is small (typically < 3 mm in diameter), organoids are stable model systems of organs and tissues that are amenable to long-term cultivation and manipulation. They are classified into those that are tissue-derived and those that are stem cell-derived. They help in both in vivo and in vitro investigation and represent one of the latest innovations in the research for a model to recapitulate the physiologic processes of whole organisms. They reduce experimental complexity, and are compliant to real-time imaging techniques, and more importantly, they enable the study of aspects of human development and disease, drug toxicity in a clear fashion that is not easily or correctly modelled in animals and 2D cell cultures. However 3D organoids have also had some limitations like vascularity, inflammatory system, etc. Despite these limitations, it is evident that organoids have great potential to revolutionize the way we approach disease modelling, drug discovery, and toxicology.

Keywords: 3D organoids, 2D cell culture, Drug discovery, Organ toxicity, High-throughput screening

References:

1. Shultz, L.D.; Brehm, M.A.; Garcia-Martinez, J.V.; Greiner, D.L. Humanized mice for immune system investigation: Progress, promise, and challenges. Nat. Rev. Immunol. 2012;12:786–98.

2. Mestas, J.; Hughes, C.C. Of mice and not men: Differences between mouse and human immunology. J. Immunol.2004; 172:2731–8.

3. Haycock J.W. 3D Cell Culture: A Review of Current Approaches and Techniques. 3D Cell Culture. Methods in Molecular Biology (Methods and Protocols).2011;695:1-15.

4. Ravi M1, Paramesh V, Kaviya SR, Anuradha E, Solomon FD.3D cell culture systems: advantages and applications. J Cell Physiol. 2015 Jan;230:16-26

5. Duarte AA, Gogola E, Sachs N, et al. BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance. Nat Methods 2018; 15: 134-40.

6. Li Z, Araoka T, Wu J, et al. 3D culture supports long-term expansion of mouse and human nephrogenic progenitors. CellStem Cell 2016:516-29.

7. Mo Li, Juan C.Izpisua Belmonte. Organoids Preclinical Models of Human Disease. N Engl J Med 2019; 380:569-79.

8. Ye Fang1 and Richard M. Eglen. Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS DISCOVERY: Advancing Life Sciences R&D: 2017; 456–72

9. Sato T, Vries RG, Snippert HJ, et al.Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459: 262-5.

10. Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature2007;449: 1003-7.

11. Hofmann C, Obermeier F, Artinger M, et al. Cell-cell contacts prevent anoikis in primary human colonic epithelial cells. Gastroenterology 2007;132: 587-600.

12. Lancaster MA, Renner M, Martin CA, et al. Cerebral organoids model human brain development and microcephaly. Nature2013; 501: 373-9.

13. Karzbrun E, Kshirsagar A, Cohen SR, Hanna JH, Reiner O. Human brain organoids a chip reveal the physics of folding. Nat Phys 2018; 14:515-22.

14. Dang J, Tiwari SK, Lichinchi G, et al.Zika virus depletes neural progenitors inhuman cerebral organoids through activation of the innate immune receptorTLR3. Cell Stem Cell 2016; 19: 258-65.

15. Se Hoon Choi, Young Hye Kim, Luisa Quinti, Rudolph E. Tanzi, Doo Yeon Kim. 3D culture models of Alzheimer's disease: a road map to a "cure-in-a-dish”.Molecular Neurodegeneration.2016; 75.

16. De Strooper B. Lessons from a failed γ-secretase Alzheimer trial. Cell. 2014;159:721–6.

17. Mariani J, Coppola G, Zhang P, Abyzov A, Provini L, Tomasini  L  et al. FOXG1-dependent dysregulation of GABA/glutamate neuron differentiation in autism spectrum disorders. Cell .2015; 162: 375–90. 

18. Jessica Hoarau-Véchot, Arash Rafii, Cyril Touboul, Jennifer Pasquier. Halfway between 2D and Animal Models: Are 3D Cultures the Ideal Tool to Study Cancer-Microenvironment Interactions. Int J Mol Sci. 2018;19:181.

19. Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol. 2014; 87:150-61.

20. Clevers H. Modeling development and disease with organoids. Cell 2016; 165:1586-97.

21. Liu B, Li S, Hu J: Technological advances in high-throughput screening. Am J Pharmacogenomics 2004;4:263–76.

22. Booij, Tijmen H., et al. “3D Cell-Based Assays for Drug Screens: Challenges in Imaging, Image Analysis, and High-Content Analysis.” SLAS DISCOVERY: Advancing Life Sciences R&D; 2019.

23. Van den Brand D., Massuger L. F., Brock R., et al. Mimicking Tumors: Toward More Predictive in Vitro Models for Peptide- and Protein-Conjugated Drugs. Bioconjug. Chem. 2017;846–56.

24. Fujii M, Shimokawa M, Date S, et al. A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis. CellStem Cell 2016; 18: 827-38.

25. Lancaster M. A., Knoblich J. A. Organogenesis in a Dish: Modeling Development and Disease Using Organoid Technologies. Science. 2014;124–5.

26. Schwartz M. P, Hou Z, Propson N. E, et al. Human Pluripotent Stem Cell-Derived Neural Constructs for Predicting Neural Toxicity. Proc. Natl. Acad. Sci. U.S.A. 2015:12516–21.

27. Gunness P., Mueller D., Shevchenko V., et al. 3D Organotypic Cultures of Human HepaRG Cells: A Tool for In Vitro Toxicity Studies. Toxicol. Sci.2013:67–78.

28. Siramshetty VB, Nickel J, Omieczynski C, Gohlke BO, Drwal MN, Preissner R.WITHDRAWN -a resource for withdrawn and discontinued drugs. Nucleic Acids Res 2016; 44(D1): D1080-6.

29. Takasato M, Er PX, Chiu HS, et al. Kidneyorganoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature 2015; 526: 564-8.

30. Li Z, Araoka T, Wu J, Liao HK2, Li M1, Lazo M, et al. 3D culture supports long-term expansion of mouse and human nephrogenic progenitors. Cell Stem Cell 2016; 19:516-29.

31. Esch E, Bahinski A., Huh D. Organs-on-Chips at the Frontiers of Drug Discovery. Nat. Rev. Drug Discov. 2015:14;248–60

32. Huh D, Leslie D.C., Matthews B. D, Fraser JP, Jurek S, Hamilton GA, et al. A Human Disease Model of Drug Toxicity-Induced Pulmonary Edema in a Lung-on-a-Chip Microdevice. Sci. Transl. Med. 2012; 4, 159ra147. 

33. Schwank G, Koo BK, Sasselli V, Dekkers J.F, Heo I, Demircan T et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. Cell Stem Cell. 2013;13:653-8.

34. Huch M., Knoblich J.A., Lutolf M.P., Martinez-Arias A. The hope and the hype of organoid research. Development. 2017;144:938–41.

35. Yin X., Mead B.E., Safaee H., Langer R., Karp J.M., Levy O. Engineering stem cell organoids. Cell Stem Cell. 2016;18:25–38.

36.  Ley K, Laudanna C, Cybulsky M.I, Nourshargh S. Getting to the site of inflammation: The leukocyte adhesion cascade updated. Nat. Rev. Immunol.2007;7:678–89.